Sperm DNA fragmentation, often abbreviated SDF, is a measure of breaks and other damage in the genetic material carried by sperm cells. Unlike conventional semen analysis, which counts sperm and grades their movement and shape, DNA fragmentation testing probes the integrity of the paternal genome itself. That matters because sperm with heavily fragmented DNA can still fertilize an egg, yet the resulting embryos may fail to develop, implant, or carry to term. Clinicians increasingly view SDF as a complementary indicator that captures something standard semen parameters miss, and researchers have spent years hunting for the biological drivers that push fragmentation upward.

Homocysteine sits at a fascinating biochemical crossroads. It is a sulfur-containing amino acid generated during one-carbon metabolism, the network of reactions that transfers methyl groups needed for DNA synthesis, repair, and methylation. When levels of folate, vitamin B12, or other cofactors are inadequate, or when metabolic regulation falters, homocysteine accumulates in the blood, a condition called hyperhomocysteinemia. Elevated homocysteine has been linked to oxidative stress, endothelial dysfunction, and cardiovascular risk, and because sperm are exceptionally vulnerable to oxidative damage to their DNA, the authors reasoned that homocysteine could plausibly serve as a metabolic correlate of sperm DNA integrity.

To test that idea, the team led by researchers at the Reproductive Center of the First Hospital of Jilin University enrolled 5,032 men attending their first fertility evaluation at a single reproductive center in China. Each participant provided a blood sample for serum homocysteine measurement and a semen sample for analysis, including assessment of DNA fragmentation by sperm chromatin structure assay. The investigators analyzed homocysteine three ways: as a continuous variable, against the clinical threshold for hyperhomocysteinemia, and across tertiles of the study population. Sperm DNA fragmentation was treated both as a continuous percentage and as a binary outcome, with abnormal SDF defined as 30 percent or higher. Body mass index was categorized as normal weight, overweight, or obesity, allowing the researchers to test whether weight status modified the relationship.

The raw numbers told a clear story. Median sperm DNA fragmentation climbed steadily across homocysteine tertiles, from 13.65 percent in men with the lowest homocysteine to 14.93 percent in the middle group and 17.10 percent in the highest. The prevalence of abnormal SDF, the clinically meaningful threshold of 30 percent or more, nearly doubled across the same gradient, rising from 10.53 percent to 12.12 percent and then 20.25 percent. Conventional semen parameters shifted in parallel: sperm concentration was comparable across tertiles, but total motility and the proportion of normally shaped sperm were both significantly lower in the highest homocysteine group, with P values below 0.001.

Statistical modeling reinforced the pattern after adjustment for age, sexual frequency, body mass index, and abstinence duration. Each 1 micromole per liter increase in serum homocysteine was associated with a 0.132 percentage-point rise in SDF, with a 95 percent confidence interval of 0.087 to 0.176, and with a modest but precise increase in the odds of abnormal SDF, an odds ratio of 1.026. Comparing extremes was more striking: men in the highest homocysteine tertile had SDF values 3.383 percentage points higher than those in the lowest tertile, and more than twice the odds of abnormal fragmentation, with an odds ratio of 2.184 and a confidence interval of 1.767 to 2.698. In epidemiological terms, that is a substantial effect for a single, easily measured blood analyte.

The most novel result, however, was the interaction with body size. When the researchers stratified their models by body mass index category, they found that the homocysteine-SDF association was significantly modified by weight status, with an interaction P value of 0.011, and that the association was strongest among men with obesity. In other words, high homocysteine and obesity do not simply add their risks together; the combination appears to amplify the relationship between the amino acid and sperm DNA damage. The authors suggest that serum homocysteine should be considered a candidate metabolic correlate of sperm DNA integrity, particularly among men with obesity.

Why might obesity act as an amplifier? The study itself is cross-sectional, so it cannot establish mechanism, but the biology offers plausible threads. Adipose tissue in obesity is a source of chronic low-grade inflammation and oxidative stress, both of which attack the tightly packed chromatin of sperm. Obesity also disrupts one-carbon metabolism and is frequently accompanied by lower folate status and altered insulin signaling, conditions that raise homocysteine. If elevated homocysteine reflects impaired methyl-donor availability, sperm may suffer both direct oxidative injury and compromised DNA repair capacity during spermatogenesis, a process that takes roughly two to three months and is exquisitely sensitive to the metabolic environment of the body.

The practical implications are worth weighing carefully. Homocysteine is a routine, inexpensive blood test, and the study hints that it could eventually help identify men whose sperm DNA is at risk even when conventional semen parameters look acceptable. That could matter for couples considering assisted reproduction, where sperm DNA fragmentation is increasingly recognized as a factor in embryo quality and outcomes. The findings also dovetail with a growing literature connecting metabolic health to male fertility, reinforcing the idea that weight management and nutritional status, including adequate folate and B vitamins that keep homocysteine in check, may protect not just the heart but the genome that men pass on.

Important caveats remain. The study was conducted at a single center among men already seeking fertility evaluation, so the results may not generalize to the broader population of healthy men. As a cross-sectional design, it captures one moment in time and cannot prove that homocysteine causes DNA fragmentation; reverse causation or confounding by unmeasured factors, such as diet, smoking, or underlying illness, cannot be excluded. The authors received no specific external funding for the work, and the study was approved by the ethics committee of the First Hospital of Jilin University with written informed consent from all participants. Future longitudinal studies and intervention trials, for example testing whether lowering homocysteine through supplementation or weight loss reduces sperm DNA damage, will be needed to determine whether this metabolic marker is merely a bystander or a genuine, modifiable lever for improving male reproductive health.

Subject of Research: The association between serum homocysteine and sperm DNA fragmentation in men undergoing fertility evaluation, and its modification by obesity

Article Title: Obesity modifies the association between serum homocysteine and sperm DNA fragmentation: a cross-sectional study of 5,032 men undergoing fertility evaluation

Article References: Tian, T., Liu, Q., Che, M., & Wang, Q. (2026). Obesity modifies the association between serum homocysteine and sperm DNA fragmentation: a cross-sectional study of 5,032 men undergoing fertility evaluation. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08917-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08917-1

Keywords: sperm DNA fragmentation, homocysteine, hyperhomocysteinemia, obesity, body mass index, male infertility, fertility evaluation, one-carbon metabolism, oxidative stress, semen parameters, cross-sectional study, reproductive medicine

The molecules at the center of the study are transfer RNA-derived fragments, or tRFs, short pieces of RNA produced when mature transfer RNAs—the workhorse molecules of protein synthesis—are enzymatically cleaved. Once dismissed as mere degradation debris, tRFs have been progressively rehabilitated over the past decade into recognized regulatory players. They can silence genes, modulate translation, and influence signaling pathways such as Wnt, MAPK and Notch. Remarkably, they are also among the most abundant small RNAs in mature sperm, and animal studies have shown that sperm tRNA fragments can carry acquired metabolic information across generations. Until now, however, no one had asked whether these fragments are altered in varicocele.

The rationale for the study rested on a suggestive parallel. Varicocele is, in essence, a varicose vein of the spermatic cord, and prior work has detected altered tRNA expression profiles in human varicose veins of the leg. One fragment in particular, tRF-36, has been shown to modulate varicose vein progression through Notch signaling in human vascular smooth muscle cells. Given that varicocele and lower-limb varicose veins share clinical associations, elevated hypoxia-inducible factor signaling and intrinsic apoptotic pathway activation, the researchers reasoned that tRFs might similarly mark the molecular pathology of varicocele in the testicular environment.

To test the idea, the team recruited 60 men with clinically diagnosed and graded varicocele—20 patients in each of grades I, II and III—alongside 20 healthy normozoospermic controls. Blood and semen samples were collected from every participant under protocols approved by the local ethics committee, with written informed consent obtained from all participants. Reproductive hormones were measured in serum, standard semen parameters were assessed according to WHO laboratory guidance, and the expression of three candidate fragments—tRF-23, tRF-36 and tRF-40—was quantified in spermatozoa using quantitative real-time PCR with the widely used comparative threshold cycle method.

The first key result was a proof of presence: all three tRFs were detectable in spermatozoa from both patients and controls, confirming that this class of regulatory RNA is indeed resident in human ejaculated sperm and is accessible for measurement. When the groups were compared directly, tRF-23 expression was elevated by 1.23-fold and tRF-36 by 1.52-fold in varicocele patients relative to controls, while tRF-40 expression was reduced to 0.9-fold of control levels. Intriguingly, none of these whole-group differences reached statistical significance, a outcome the authors interpret cautiously given the modest sample size and the heterogeneity that varicocele introduces when patients of all grades are pooled together.

The picture changed dramatically when the researchers stratified patients by disease severity. Here, tRF-36 emerged as the standout molecule. Its expression fell in a pattern that tracked advancing disease, culminating in a significant 4.52-fold decrease in grade III varicocele patients compared with those harboring grade I disease, a difference that was statistically robust at a p value of 0.010. In other words, the fragment that had appeared mildly elevated in the pooled analysis was in fact being driven downward in the most severe cases, masked at the aggregate level by the comparatively higher expression in milder disease. This grade-dependent signature suggests that tRF-36 is not simply a bystander but may participate in the escalating molecular damage that accompanies advanced varicocele.

Correlation analyses added a second layer of meaning. All three tRFs displayed significant interrelationships with one another, hinting at coordinated regulation of this small RNA population within spermatozoa. More striking was their shared behavior with respect to semen quality: each of the three fragments was negatively correlated with sperm concentration, one of the cardinal parameters by which male fertility is judged. A negative correlation implies that lower fragment levels accompany lower sperm counts, consistent with the possibility that disruption of tRNA-derived RNA homeostasis in sperm parallels, and potentially contributes to, the impaired spermatogenesis that varicocele produces through mechanisms such as venous stasis, elevated testicular temperature, oxidative stress and reflux of toxic adrenal metabolites.

The study also examined whether tRF expression relates to circulating reproductive hormones, which serve as endocrine readouts of testicular function. While the abstract reports that the analysis set out to determine associations between the fragments and hormone levels as well as semen quality, the headline statistical signals in this first report are the grade-dependent tRF-36 change and the negative correlations with sperm concentration rather than strong hormone associations. This positions the fragments, at this stage, as markers more tightly coupled to the cellular output of the testis than to its endocrine regulation, a pattern that future studies with larger cohorts may refine.

What makes the work notable is less the size of the effects in pooled comparisons than the conceptual milestone it represents. Previous investigations of varicocele’s molecular footprint have focused on sperm DNA methylation patterns, oxidative stress-related microRNAs, hypoxia-associated long noncoding RNAs and transcriptome-wide signatures from exome and RNA sequencing. The new study extends this catalog to tRFs, a class whose abundance in sperm and demonstrated role in intergenerational epigenetic inheritance give it particular biological weight. If varicocele remodels the sperm small RNA payload, then the consequences of the condition could in principle extend beyond fertility itself, echoing evidence that paternal sperm tsRNAs can transmit acquired traits to offspring.

The translational possibilities are tantalizing but deliberately restrained. A fragment whose expression distinguishes grade III from grade I disease could, with validation, become a noninvasive molecular indicator of varicocele severity, complementing clinical grading and semen analysis and potentially informing decisions about surgical repair. tRFs are also attractive as biomarkers because they are chemically stable and readily measured in reproductive fluids and extracellular vesicles, where other tRNA-derived fragments have already been proposed as predictors of outcomes in assisted reproduction and microdissection testicular sperm extraction. The authors caution, appropriately, that their findings are the first link rather than the last word, and that larger, longitudinal and post-treatment studies will be needed to establish whether tRF-36 responds to varicocelectomy, whether it predicts postoperative recovery of semen quality, and whether its connection to Notch signaling in vascular disease is mirrored in the testicular microvasculature. For now, the study furnishes a fresh molecular suspect in one of andrology’s oldest mysteries, and a demonstration that the smallest fragments of our RNA repertoire may carry some of the loudest signals about male reproductive health.

Subject of Research: Sperm tRNA-derived fragment expression in varicocele and its association with disease severity, semen parameters and reproductive hormones

Article Title: Sperm tRNA-Derived Fragment-36 Expression in Varicocele: Associations with Disease Severity, Semen Parameters and Reproductive Hormones

Article References: Sperm tRNA-Derived Fragment-36 Expression in Varicocele: Associations with Disease Severity, Semen Parameters and Reproductive Hormones. (n.d.). https://doi.org/10.1007/s43032-026-02210-8

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02210-8

Keywords: varicocele, male infertility, tRNA-derived fragments, tRF-36, spermatozoa, sperm concentration, reproductive hormones, semen parameters, non-coding RNA, spermatogenesis, biomarkers, andrology